Any developer building a clinical AI product faces an early, consequential decision: ground the system in unrestricted open-web search, or connect it to a curated, licensable medical knowledge source instead. The evidence-hierarchy and curated-source arguments covered throughout this content series apply with particular force here, since a developer's sourcing choice shapes every downstream answer their product will ever produce.
Why unrestricted web search is a poor foundation
Open-web content is not filtered for clinical relevance or accuracy, carries no consistent editorial standard, and mixes genuinely authoritative sources with unreliable ones in a way that is extremely difficult for an automated system to reliably distinguish at scale. A product built on this foundation inherits every one of these problems by default.
The options worth knowing
AMBOSS MCP, covered in detail elsewhere in this content series, offers external AI agents structured access to AMBOSS's curated articles, drug information, flowcharts, calculators, scores and clinical cases, with outputs linking back to the original content.
ClinicalKey AI APIs offer access to Elsevier's substantial existing publisher relationships, spanning more than a thousand medical journals and organisations, for developers building within an enterprise or institutional context.
UpToDate enterprise integrations offer access to UpToDate's expert-authored content within a broader enterprise technical relationship, typically requiring institutional agreement rather than open developer access.
DynaMed APIs and SMART on FHIR services offer a further established, evidence-based reference source with its own integration pathway for developers building clinical applications.
National guideline APIs, where they exist, offer direct access to a specific country's authoritative clinical guidance, though availability and technical maturity vary considerably by jurisdiction.
Comparing across the dimensions that matter for a developer
Content breadth, editorial curation, drug information depth, citation availability, licensing terms, geographic relevance, and update frequency all vary substantially across these options, and a developer's choice should be driven by which specific combination matches their product's actual use case, rather than defaulting to whichever option is easiest to integrate technically.
Four distinct things a developer needs to keep separate
Knowledge access, retrieving curated medical content. Patient-data access, reading information about a specific patient, a separate technical and governance concern covered in detail elsewhere in this series with respect to FHIR specifically. The reasoning model, the AI system actually combining knowledge and patient data into a usable output. And clinical action, anything the resulting system does beyond presenting information for a human to review. Conflating these four, treating a knowledge-access integration as though it automatically confers safe reasoning or action capability, is a genuine and consequential design error.
AMBOSS as the clearest current MCP-specific example
Among the options listed here, AMBOSS's MCP server offers the clearest, most directly documented example of a curated medical knowledge base specifically opened for external AI agent use, making it a useful reference point for understanding what this category of integration looks like in practice.
The risks of downstream transformation worth taking seriously
A source can be genuinely reliable while an external agent's summary or transformation of that source is not. Citations can be lost as content passes through an external system's own processing. And recommendation strength or nuance present in the original source can be distorted, whether through simplification, mistranslation across contexts, or simply an external agent's own reasoning layer introducing error not present in the underlying knowledge itself.
A UK section worth adding directly
NICE, CKS, SIGN and SmPC medicines sources each require appropriate licensing and attribution before being incorporated into any third-party product, and developers building UK-facing clinical AI should treat this as a genuine legal and governance requirement, not an optional courtesy. A future iatroX developer interface could, in principle, provide a clinically curated UK layer analogous to what AMBOSS MCP offers for its own US-oriented content.
Being clear about what does not currently exist
No speculative iatroX developer API should be presented as currently available; this article describes a plausible future direction consistent with the broader pattern this comparison documents, not an existing product.